Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Rhea-AI Summary

Actinium Pharmaceuticals (NYSE American: ATNM) will present two abstracts at the AACR Annual Meeting 2026 in San Diego on April 21, 2026, within the Experimental and Molecular Therapeutics category.

Abstract details (titles and full text) will be publicly available March 17, 2026 at 4:30 PM ET via the AACR Online Program Planner. Presentations focus on ATNM-400 and Actimab-A programs and radiopharmaceutical theranostic platforms using Ac-225.

News Market Reaction

-2.70%

1 alert

-2.70% News Effect

-$1000K Valuation Impact

$36M Market Cap

0.2x Rel. Volume

On the day this news was published, ATNM declined 2.70%, reflecting a moderate negative market reaction. This price movement removed approximately $1000K from the company's valuation, bringing the market cap to $36M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AACR meeting dates: April 17–22, 2026 Abstracts count: 2 abstracts Embargo lift date: March 17, 2026, 4:30 PM ET +5 more

8 metrics

AACR meeting dates April 17–22, 2026 AACR Annual Meeting 2026 in San Diego

Abstracts count 2 abstracts ATNM-400 and Actimab-A AACR 2026 presentations

Embargo lift date March 17, 2026, 4:30 PM ET AACR abstracts become publicly available

Session date April 21, 2026 AACR 2026 Experimental and Molecular Therapeutics session

Session time 2:00 PM – 5:00 PM PT Radiopharmaceutical Platforms for Theranostic Precision Oncology

Poster board numbers 18 and 21 Locations for Actinium AACR 2026 posters

Poster numbers 5824 and 5827 AACR 2026 poster identifiers for Actinium

Isotope Ac-225 High-linear energy transfer radionuclide used in targeted radiotherapy

Market Reality Check

Price: $1.04 Vol: Volume 95,035 is at 0.81x...

normal vol

$1.04 Last Close

Volume Volume 95,035 is at 0.81x the 20-day average, indicating subdued pre-news activity. normal

Technical Shares trade below the 200-day MA of 1.51 at 1.11, near the 52-week low of 1.0292 and 53.94% below the 2.41 52-week high.

Peers on Argus

Biotech peers show mixed moves: GNTA -4.56%, PYPD -3.70%, VTVT -3.37% versus PDS...

1 Down

Biotech peers show mixed moves: GNTA -4.56%, PYPD -3.70%, VTVT -3.37% versus PDSB +3.06% and CUE +2.17%. Momentum scanner only flags PYPD moving down, suggesting no clear sector-wide pattern tied to this AACR update.

Historical Context

5 past events · Latest: Dec 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 12	Preclinical data update	Positive	+4.1%	New ATNM-400 preclinical data with strong anti-tumor activity at SABCS 2025.
Dec 01	Data presentation news	Positive	-0.7%	Announcement of potent efficacy and resistance-overcoming ATNM-400 data for SABCS.
Nov 17	Strategic platform focus	Positive	+14.2%	Feature on ATNM-400 and radiotherapy strategy including patent estate and market context.
Nov 04	Conference data preview	Positive	-2.2%	Announcement of upcoming ATNM-400 data at 2025 San Antonio Breast Cancer Symposium.
Nov 03	Investor conference	Neutral	-3.5%	Participation in Stephens Biotechnology Virtual Fireside Chat with investor meetings.

Pattern Detected

Recent scientific and strategic updates often led to mixed price reactions, with some ATNM-400 data catalysts drawing strong gains while others saw flat or negative responses.

Recent Company History

Over the last few months, Actinium has repeatedly highlighted its ATNM-400 radiotherapy platform. On Nov 3, 2025 and Nov 4, 2025, the company framed ATNM-400 as a pan-tumor asset and prepared SABCS presentations. Subsequent December 2025 releases emphasized potent anti-tumor activity and resistance-overcoming data, with price reactions ranging from about -2% to +14%. Today’s AACR abstract announcement continues this pattern of conference-focused visibility for ATNM-400 and Actimab-A.

Market Pulse Summary

This announcement highlights Actinium’s continued effort to showcase ATNM-400 and Actimab-A, with tw...

Analysis

This announcement highlights Actinium’s continued effort to showcase ATNM-400 and Actimab-A, with two abstracts accepted at AACR 2026 spanning solid tumors and hematologic oncology. It extends a pattern of frequent conference engagement and preclinical disclosures seen through late 2025. Investors may focus on the detailed data release on March 17, 2026, the quality of any efficacy or safety signals presented, and how these align with the company’s broader radiotherapy platform strategy and ongoing clinical timelines.

Key Terms

radiotherapies, radiopharmaceutical, theranostic, oncology, +4 more

8 terms

radiotherapies medical

"a pioneer in the development of differentiated targeted radiotherapies"

Radiotherapies are medical treatments that use controlled beams of radiation to damage or destroy abnormal cells, most commonly cancer, while sparing nearby healthy tissue as much as possible. For investors, they matter because development, approval, and adoption of these treatments drive sales, require specialized equipment and regulatory clearance, and influence reimbursement and long-term clinical outcomes—factors that affect a company’s revenue, risks, and growth prospects.

radiopharmaceutical medical

"Radiopharmaceutical Platforms for Theranostic Precision Oncology"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

theranostic medical

"Radiopharmaceutical Platforms for Theranostic Precision Oncology"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

oncology medical

"Theranostic Precision Oncology on April 21, 2026."

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

high-linear energy transfer (LET) medical

"Leveraging the high-linear energy transfer (LET) of Ac-225"

High-linear energy transfer (LET) describes radiation particles that deposit a large amount of energy over a short distance as they travel through tissue, producing dense, localized cell damage rather than spread-out, gentle effects. For investors, whether a therapy or radiopharmaceutical uses high-LET radiation influences clinical effectiveness, side effects, regulatory scrutiny and liability risk—think of a tightly focused hammer blow that can be more effective on a target but also risks nearby healthy tissue.

Ac-225 medical

"Leveraging the high-linear energy transfer (LET) of Ac-225"

Ac-225 (actinium-225) is a rare radioactive isotope used as the active payload in targeted alpha therapy, a cancer treatment that delivers very powerful, short-range radiation directly to tumor cells. For investors, Ac-225 matters because its scarce, complex manufacturing and strict regulatory handling act like a critical ingredient in a drug supply chain—shortages or production hurdles can delay trials, raise costs and materially affect the commercial prospects and valuation of companies developing such therapies.

cytotoxicity medical

"to deliver potent, tumor-specific cytotoxicity"

Cytotoxicity is the ability of a substance to kill or damage living cells. Investors watch cytotoxicity results because they indicate whether a drug or chemical is likely to be effective against targeted cells (for example, cancer cells) and whether it poses safety risks to healthy tissue, which affects clinical success, regulatory approval, and commercial potential—similar to knowing if a powerful weed killer also harms the lawn around the weeds.

pan-tumor medical

"Building a radiotherapy franchise comprised of multiple pan-tumor assets"

Pan-tumor describes a treatment approach or approved therapy that targets a specific genetic or molecular feature found across many different kinds of cancer, rather than being limited to one organ or tissue. For investors, pan-tumor relevance signals a potentially much larger market and simpler regulatory path—like a master key that can open many doors instead of a key made for a single lock—affecting sales potential, trial design and valuation.

AI-generated analysis. Not financial advice.

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.

Both abstracts are scheduled for presentation in the Experimental and Molecular Therapeutics category under the session titled Radiopharmaceutical Platforms for Theranostic Precision Oncology on April 21, 2026.

In accordance with AACR embargo policies, details of the abstracts, including titles and full text, will become publicly available on March 17, 2026, at 4:30 PM ET via the AACR Online Program Planner.

Presentation Details

Presentation #1:

Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 18
Poster Number: 5824

Presentation #2:

Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 21
Poster Number: 5827

Actinium's Platform Strategy for Long-Term Value Creation

The AACR 2026 data will highlight Actinium's differentiated biology-driven approach to targeted radiotherapy development including:

• Targeting resistance-associated biology rather than tumor surface expression alone
• Leveraging the high-linear energy transfer (LET) of Ac-225 to deliver potent, tumor-specific cytotoxicity
• Building a radiotherapy franchise comprised of multiple pan-tumor assets

Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, commented, "We are pleased to have two abstracts accepted for presentation at AACR 2026. Participation in this meeting provides an important opportunity to engage with the Oncology research community. We look forward to sharing additional details once the abstracts are publicly released in accordance with AACR guidelines."

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. ATNM-400, Actinium's lead product candidate, is a novel, first-in-class, and multi-indication Actinium-225 (Ac-225) in development for prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. The antigen specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), contributes directly to disease progression, poorer survival outcomes, and continues to be expressed at a high level even after androgen receptor inhibitor (ARPI) and Pluvicto^® treatment. ATNM-400 is supported by preclinical data demonstrating tumor-specific uptake, higher efficacy than androgen receptor inhibitor enzalutamide (Xtandi^®) and 177Lu-PSMA-617 radiotherapy, the active agent in Pluvicto^®, durable tumor control and potent efficacy in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617. In addition, ATNM-400 has demonstrated synergy with enzalutamide. In NSCLC, ATNM-400 showed superior efficacy to EGFR targeting therapies including osimertinib (TARGRISSO^®, AstraZeneca), Dato-DXd (DATROWAY^®, AstraZeneca/Daiichi Sankyo) and amivantamab (RYBREVANT^®, J&J) with synergistic activity in combination with osimertinib. In breast cancer, ATNM-400 works as monotherapy in triple-negative breast cancer, hormone-positive breast cancer and also in HER2-therapy trastuzumab (HERCEPTIN^® Roche) resistant breast cancer and endocrine therapy-resistant breast cancer models. The data generated to date with ATNM-400 supports its potential across treatment settings to be used either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA^® and OPDIVO^® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds approximately 240 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:
investorrelations@actiniumpharma.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-two-abstracts-at-the-2026-aacr-annual-meeting-302689485.html

SOURCE Actinium Pharmaceuticals, Inc.

FAQ

What is Actinium (ATNM) presenting at AACR 2026 on April 21, 2026?

Actinium will present two abstracts on April 21, 2026 in the Experimental and Molecular Therapeutics category. According to Actinium, presentations cover the ATNM-400 and Actimab-A programs and radiopharmaceutical theranostic platform development using Ac-225.

When will the full AACR 2026 abstracts from Actinium (ATNM) be publicly released?

The full abstracts will be released March 17, 2026 at 4:30 PM ET via the AACR Online Program Planner. According to Actinium, AACR embargo policies require that titles and full text become public at that time.

Where and when are Actinium's (ATNM) AACR poster presentations scheduled?

Both posters are scheduled April 21, 2026 during the Radiopharmaceutical Platforms session, 2:00–5:00 PM PT in Poster Section 16. According to Actinium, poster board numbers are 18 and 21, poster numbers 5824 and 5827.

What scientific focus will Actinium's (ATNM) AACR 2026 abstracts emphasize?

The abstracts emphasize a biology-driven targeted radiotherapy approach prioritizing resistance-associated biology over surface expression. According to Actinium, the work highlights Ac-225 high-LET cytotoxicity and a pan-tumor radiotherapy franchise strategy.

How can investors or researchers access Actinium (ATNM) AACR 2026 presentation details?

Presentation details and full abstracts will be accessible via the AACR Online Program Planner after the March 17, 2026 embargo lift. According to Actinium, interested parties should consult the AACR planner for titles, texts, and poster locations.